The Zephyr Endobronchial Valve, Pulmonx’s minimally invasive treatment for severe emphysema, was recently found to improve breathing, quality of life, and activity for patients in a U.S. clinical trial called LIBERATE. The treatment met all of the trial’s primary and secondary endpoints, or goals, after one year. Emphysema is a…
A new study showed that 21% of chronic obstructive pulmonary disease (COPD) cases can be attributed to occupational exposures, particularly exposure to biological dust, pesticides, gases, and fumes. The study, “Occupational exposures and 20-year incidence of COPD: the European Community Respiratory Health Survey,” was published in the…
Top-line results of a Phase 3 trial showed that treatment candidate Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), AstraZeneca and its subsidiary MedImmune announced. The multi-center, double-blind GALATHEA (NCT02138916) study is part of AstraZeneca’s VOYAGER…
Verona Pharma’s treatment candidate for chronic obstructive pulmonary disease (COPD) RPL554 works to open the airways of the lungs, aiding bronchodilation, when used with Spiriva (tiotropium), and its newer inhaled formulation is safe and appropriate for patient use, clinical trial data being presented at ATS 2018 report. RPL554 is designed…
The blood growth factor called granulocyte-colony stimulating factor (G-CSF) underlies airway inflammation and lung tissue destruction in COPD, but also the symptoms in other tissues, including the heart and bone, a new study shows. The findings of Australian scientists at Monash University and the University of Melbourne suggest that clinical…
Blocking a cellular pathway related to cholesterol metabolism shows early promise in treating chronic obstructive pulmonary disease (COPD), a German study in mice reports. The research, “Cholesterol metabolism promotes B-cell positioning during immune pathogenesis of chronic obstructive pulmonary disease,” was published in the journal EMBO Molecular…
The U.S. Food and Drug Administration (FDA) recently approved an expanded indication for Trelegy Ellipta, meaning the medicine can now be used by doctors there to treat a broader population of chronic obstructive pulmonary disease (COPD) patients. This new indication is as a once daily, long-term maintenance treatment of…
A recently published survey showed that both patients and healthcare providers place less importance on inhaler devices than medication in the treatment of chronic obstructive pulmonary disease (COPD). Even though past studies have shown that learning good inhaler techniques is key to achieving optimal COPD care, the survey…
Treatment with the triple-combination therapy Trelegy Ellipta reduced exacerbations in chronic obstructive pulmonary disease (COPD) and improved patients’ lung function and quality of life, according to a Phase 3 trial. The Phase 3 IMPACT study compared Trelegy to other common COPD medications in 10,355 patients in 37 countries, according to…
Applications for the new ATS Foundation/Insmed Research Award in Non-Tuberculous Mycobacteria (NTM) Lung Disease will open soon to provide one-year funding of $50,000 to researchers seeking to find better ways to prevent, diagnose and treat this complex condition. NTM lung disease is a chronic and progressive condition caused by…
Get regular updates to your inbox.